GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs from China two years ago, according to an executive.
- Home |
- GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
- September 22, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
